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ABSTRACT
Recently it has been shown that leukocytes are capable of producing prolactin (PRL).
Evidence of extra-pituitary PRL (ePRL) production is so far been limited to primates and is not
shared across other mammal species such as mice and rats. While ePRL is characterized as an
identical protein to traditional pituitary PRL, it is controlled under an alternative promoter and
is thus regulated differently from pituitary PRL. Little is known about what regulates ePRL or its
direct role in human physiology, but given that PRL has well over 300 described functions, it is
likely that the autocrine and paracrine effects of this hormone could have far reaching
implications in overall physiology. This work takes some of the first steps in understanding how
leukocyte ePRL is regulated. Our results show that, adrenergic hormones are one key stimulus
in ePRL expression in monocytes/macrophages. This is particularly intriguing considering the
opposing role of these two signals in settings such as adipose tissue where adipose tissue
macrophages are constantly exposed to pro-lipolytic adrenergic hormones that would in turn
stimulate production of an anti-lipolytic hormone, PRL. Further, our work shows that the
inflammatory phenotype of the leukocytes influences basal expression of PRL and overall ePRL
expression increases significantly as monocytes differentiate into macrophages, as is a common
occurrence in adipose tissue. The final portion of our work shows how
monocytes/macrophages also respond to preadipocytes directly. These stem cell precursors to
mature adipose cells release an unknown factor that stimulates ePRL production in
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monocytes/macrophages. Analysis of our gene array shows many of the genes stimulated by
adipose stem cells alongside PRL are important genes in tissue regeneration and remodeling, a
possible role that fits well with known effects of PRL. Understanding such primate specific
interactions between the immune system and major metabolic tissues such as adipose fills vital
gaps in knowledge that may explain why so many treatments fail when transitioning from
mouse models to humans.
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CHAPTER ONE: GENERAL INTRODUCTION
As the proposed studies describe the use of various cell types, a bird’s eye view of the cell types
is given below:

Monocytes
Monocytes are a type of leukocyte and a key component of the innate immune system.
They are produced in the bone marrow from hematopoietic stem cells1. Originally defined by
their morphology, they are now commonly identified by the cell surface marker Cluster of
Differentiation 14 (CD14)2. CD14 plays an important role in both inflammatory responses where
it acts as a co-receptor for TLRs recognizing LPS 3,4, and anti-inflammatory responses where it is
an important mediator in recognizing and phagocytizing apoptotic cells.5
Monocyte subtypes can be further distinguished by the secondary marker CD16 and its
ratio to CD14 expression. They are generally broken down into 3 subtypes: classical
CD14++/CD16-, intermediate CD14++/CD16+, and non-classical CD14+/CD16++.2 The classical
subtype makes up the vast majority of monocytes in the blood, commonly constituting around
80-90% of monocytes, while the non-classical subtype typically constitutes around 10% of total
monocytes and are more inflammatory in nature.6,7 While there is some plasticity between the
types, it is generally believed that there is a developmental relationship where classical
monocytes give rise to non-classical monocytes with intermediate monocytes being a transitory

1

subtype.7,8 All subtypes are capable of differentiating into macrophages although non-classical
show a greater propensity for doing so, while classical monocytes are the only subset capable
of differentiating into dendritic cells (DCs).9
Even within these subtypes monocytes are extremely plastic in their abilities. They help
regulate both inflammatory and anti-inflammatory immune responses by releasing cytokines
and antimicrobial factors10, and travel to sites of infection by following chemoattractants such
as monocyte chemoattractant protein-1 (MCP-1)11,12 where their differentiation into DCs and
macrophages extends their indirect roles in homeostasis even farther.

Macrophages
Macrophages are one of the primary professional phagocytes in the human body and a
key component of the innate immune system. Originally it was thought that all macrophages
were derived from monocytes, termed “monocyte derived macrophages” (MDM). However, it
is now understood that the majority of the macrophage population actually stems from
embryonic development.13 Nonetheless, MDMs still play a significant role in the human body
and fulfill vital roles in maintaining homeostasis and supporting other macrophage populations.
MDM development begins when patrolling monocytes are targeted towards sites of
inflammation where they then differentiate and migrate into the target tissue14. MDMs are
most commonly recruited during periods of acute stress, such as in response to wounding,
where a rapid increase in macrophage populations are needed to overcome pathogens or
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return the tissue to homeostasis.15,16 For the most part, there is a large overlap in the functions
and abilities of MDM’s and most embryonically derived macrophages (EDM), and both
populations tend to work synergistically.
EDMs primarily include tissue resident macrophages that have functions highly
specialized to their resident tissue, are capable of dividing in the tissue to increase numbers,
and serve vital roles in homeostasis in the resident tissue13. Many tissues differ in the
contribution of MDMs and EDMs to their macrophage populations. Microglial cells in the brain
for instance are almost exclusively of embryonic origin17 while Kupffer cells in the liver tend to
be supplemented with higher levels of MDMs.18 The focus on macrophages of the embryonic
lineage has grown as studies have shown these populations have a much greater capacity for
self-replication than previously thought. As a result, many tissue resident macrophages are able
to maintain and expand populations when necessary and assistance from the MDM population
is mostly required during times of acute stress and infection.19

Polarization
Macrophages are some of the most plastic cells within the human body and can be
programmed for a variety of important functions. Traditionally, macrophage polarization has
been viewed as a binary programming system designated by M1 polarization indicating proinflammatory profile and M2 polarization indicating an anti-inflammatory profile20. Many
recent studies and more complex genetic analysis have shown that macrophage phenotypes
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are far more complex and can be a blend of both M1 and M2 and can even include traits that
fall entirely outside of the traditional M1/M2 spectrum.21-23
M1 inflammatory macrophages play particularly important roles in defending the body
against invading pathogens by killing and phagocytizing bacteria or virus infected cells21 . They
are hallmarked by their production of inflammatory cytokines and are often defined by their
increased expression of inflammatory cytokines such as tumor necrosis factor- alpha (TNFa) and
interleukin-6 (IL-6). They also derive most of their energy via glycolysis using carbohydrates as a
primary fuel source.24
M2 macrophages are designated by their production of anti-inflammatory cytokines
such as MRC-1 and IL-10. They derive most of their energy via beta-oxidation of fatty acids.24
These macrophages play an essential role in tissue repair and remodeling25 but along the same
lines, have also been shown to be permissive or even protective towards tumor cells as many of
those repair and remodeling functions can be used to create a microenvironment more
conducive to tumor growth.26

Adipose Tissue
Traditionally thought of as a simple lipid storage tissue, adipose tissue is starting to be
recognized for the complex endocrine organ that it is. Adipose tissue is a complex milieu of not
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only adipocytes, but also tissue matrix, nerve tissue, stromovascular cells, stem cells, and
immune cells.27 The major constituents of adipose tissue are discussed below.

Adipocytes
Clearly the stars of the adipose tissue are the cells from which it derives its name.
Adipocytes function primarily as lipid storage cells. Their key feature is the development of a
large lipid droplet that stores neutral lipids in the form of triglycerides.28 These lipid droplets
provide the densest form of energy storage in the human body, as fatty acids have large ATP
production potential and storing energy in the form of lipids avoids the water retention that
accompanies carbohydrate storage in forms like glycogen.29
The triglycerides within the adipocytes are formed from a variety of sources. Dietary fats
are able to be stored directly through specialized uptake systems. Fats are absorbed in the
intestine and transported to the liver as chylomicrons via the lymphatic system. Chylomicrons
undergo lipolysis in the plasma, giving rise to “remnant” particles that are absorbed by the liver.
Once in the liver, hepatocytes repackage the fats into lipoprotein particles, primarily VLDL using
lipoprotein B as the primary organizing protein30. These particles are then able to more easily
travel through the blood stream where they reach adipocytes and fats are mobilized out of the
particle and into the adipocyte.
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Lipid uptake is accomplished via lipases and esterases, such as lipoprotein lipase (LPL)
that works to release free fatty acids and cholesterol from the particle, and receptors such as
CD36 and FATP that allow uptake of FFA into the cell.31 Once inside the adipocyte, free fatty
acids are esterified to glycerol in groups of three forming neutral lipid triglycerides. Cholesterol
is esterified to a free fatty acid. These two esterified lipid products make up the bulk of the lipid
droplet in mature adipocytes.28 Naturally, increase in adipocyte size is accompanied by the
need to synthesize membrane components such as phospholipids.
Aside from direct uptake of lipids, adipocytes also have an enormous capacity for
lipogenesis via carbohydrate metabolism.32-34 Glucose is broken down to pyruvate that then
enters the tricarboxylic (TCA) cycle. Citrate from the TCA cycle can then be converted to acetylCoA, and then malonyl-CoA which acts as an important starting molecule from which free fatty
acids can be built35. After the formation of free fatty acids, they can then be incorporated into
triglycerides just as FFA taken directly from the diet. This process is stimulated via insulin
signaling which allows adipocytes to store carbohydrates as fat when blood sugar spikes. 35

Preadipocytes and adipocyte differentiation.
Adipocytes are under constant turnover and replacement. Such turnover is possible
thanks to a population of mesenchymal stem cells more specifically referred to as adipose stem
cells (ASC) or preadipocytes (PA). While the total number of adipocytes in any individual’s
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adipose depots remains constant throughout their life, the population is replaced at a rate of
about 10% per year and all adipocytes are replaced over about an 8-year cycle36.
ASC typically retain the ability to differentiate into a variety of cells. Differentiation into
mature adipocytes specifically is achieved through activation of the master transcription factor
peroxisome proliferator-activated receptor gamma (PPARy).37 However, studies show that this
“stemcellness” is reduced in ASC from obese patients and many of the ASC population is
already committed towards adipocyte differentiation with a reduced ability to differentiate into
other cell types.38
This differentiation process is essential to a healthy accumulation and storage of fat.
Factors that inhibit differentiation of adipocytes, such as TNFa, plasminogen activator inhibitor1 (PAI-1), and many other inflammatory cytokines, can cause undue burden on the remaining
cell population to accumulate and store fat. This stress leads to metabolic dysregulation like
insulin resistance, adipocyte cell death, further inflammation, and then reinforcement of many
of the same signals that inhibit differentiation thus creating an inflammatory feedback loop.39,40
Factors that promote this differentiation process have been shown to aid in healthy fat
accumulation. Bringing more adipocytes online allows the cell population to share the burden
of fat accumulation and storage and thus lowers overall cellular stress. This allows an individual
to store more energy without many of the other chronic issues that often accompany obesity.41
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Adipose Tissue Macrophages
The next most common cells within the adipose tissue after adipocytes are adipose
tissue macrophages (ATM). ATMs are resident within adipose but their overall numbers can
fluctuate considerably under different conditions. In healthy, lean individuals ATMs comprise
about 15% of the total adipose cell population; however, during excessive weight gain there is a
large influx of macrophages into the adipose and numbers can climb to as high as 50-60% of
total cells in obese individuals.42,43 It is not well established as to why there is such a large
expansion of the ATM population during obesity but many studies have shown that adipocytes
are capable of secreting a number of immune chemoattractants, such as MCP-1 and CCL5,
during obesity.44,45
It is still debated as to which factors have the greatest influence over macrophage
infiltration and many of the roles they perform in the tissue are still being uncovered. So far, it
is known that these ATMs play an important role in scavenging both FFAs leaked from overlystressed adipocytes and the dying adipocytes themselves46. ATMs form “crown-like” structures
as they encircle stressed and dying adipocytes47,48. ATMs have been shown to accumulate so
many FFAs themselves that lipid droplets develop in the immune cells forming foam cells more
commonly seen within atherosclerotic plaques.47,49
On top of this influx of macrophages, it has also been shown that the polarization of the
macrophages also differs between lean and obese individuals. ATM’s in lean adipose depots
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tend towards an anti-inflammatory M2 polarization while ATMs from obese adipose depots
tend towards an inflammatory M1 phenotype50. This has important implications in overall
adipose physiology as the increased production of inflammatory cytokines characteristic of M1
macrophages can affect a variety of adipose functions such as differentiation mentioned above,
and lipid metabolism.51,52

Prolactin and Prolactin Receptor
Pituitary PRL
Prolactin (PRL) is a 23kDa peptide hormone traditionally known for its role in
coordinating milk production in mammals. It belongs to the cytokine class-1 receptor
superfamily and more specifically the placental lactogens, which also includes growth hormone
(GH) and placental lactogen (PL). PRL is primarily produced by lactotrophs in the anterior
pituitary where it is released in a pulsatile fashion.53
In pituitary lactotrophs, PRL is under the control of the Pit-1 promoter54. The classical
stimulators of pituitary PRL (pPRL) are suckling, stress, and ovarian steroids such as estrogen 53.
The most well defined inhibitor of pPRL expression is dopamine which negatively regulates PRLs
secretion55. Pituitary PRL is also regulated through secretory granules that allow a buildup of
PRL within the lactotrophs that can then be delivered in a much stronger burst than if simply
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secreted as transcribed.56 This is a key factor in regulating PRLs pulsatile release from the
pituitary.
While PRL is traditionally thought of for its role in coordinating lactation in mammals,
PRL itself is an evolutionarily ancient protein whose lineage reaches far enough back to be
expressed in both birds and fish.57 PRL is also exhibits extreme diversity in its bioactivity with
well over 300 defined actions spanning multiple tissues and systems in the human body
including the immune system, vasculature endothelial cells, and major metabolic tissues such
as adipose.58

Extra-pituitary prolactin
More recently, it has been discovered that PRL production is not limited to the pituitary.
In fact, a variety of tissues outside the pituitary have now been discovered produce PRL de
novo. These tissues and systems include the decidua, immune system, brain, and myometrium,
with more being discovered every year.59 Studies show the ePRL protein is transcribed directly
from the same gene as classical pPRL and indeed has an identical protein structure.60 Where
these two sources of PRL differ is in their regulation. ePRL falls under the control of an
alternative promoter which results in differential regulation and the addition of a 150bp
promoter to the ePRL mRNA.60 As a result, much of what is known about PRL regulation in the
pituitary does not translate to ePRL regulation. Classical regulators of pituitary PRL such as
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dopamine, thyrotropin-releasing hormone (TRH), vasoactive intestinal peptide (VIP), and
estrogen, show no significant regulatory effect on ePRL in cell culture.59
On the other hand, specific regulators of ePRL expression are far less well defined and
can differ slightly depending on the tissue.61 So far, cAMP activation has been shown to be
effective in stimulating ePRL expression in the decidua62 and lymphoid cells 63,64_ENREF_63
although these results have not always held up across all tissue types.61 Work done in our lab is
in agreement with this concept though, showing that adrenergic hormones, which signal
through cAMP, are able to stimulate ePRL in monocytes and MDMs.65 Further, these extrapituitary sites lack the storage granules present in pituitary lactotrophs and as a result, any PRL
synthesized is likely immediately excreted into the surrounding space59. Far more work is
needed however to uncover the regulational complexities of ePRL across various cell types.
The concept that ePRL is an identical protein that is regulated differently to pituitary PRL
is a particularly important concept to consider when looking to apply previous studies to
current work. As a signaling hormone, much of the previous work on PRLs bioactivity and
characteristics would be largely applicable to better understanding the functions of ePRL, and
indeed many studies have shown that the autocrine and paracrine effects of ePRL mirror those
of pPRL.66 Nonetheless, autocrine and paracrine PRL signaling could have vastly different effects
on whole body physiology thanks to its unique regulation and delivery.
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Vasoinhibins (PRL fragments)
PRL can undergo a variety of post-translational modifications including dimerization,
polymerization, phosphorylation, glycosylation, and proteolytic cleavage.53 In general, most of
these post-translational modifications tend to lower PRLs biological activity with the exception
of proteolytic cleavage.
Cleavage of the PRL protein results in a 16kDa N-terminal protein fragment called
vasoinhibin that no longer binds the PRLR but instead shows entirely separate biological
activity67. A number of different proteases have been shown to cleave PRL into this bioactive
fragment including multiple matrix metalloproteases 68,69 and cathepsin-D67,70. The reason that
such a wide variety of proteases are able to create these peptides is that bioactivity is
maintained in the fragments across cleavages at various sites and in fact, N-terminal fragments
from 12-17kDa have been shown to all be bioactive as vasoinhibins.68 Further, due to sequence
homology, similar cleavage of both GH and PL leads to fragments of the same size and
bioactivity, lending credence to the idea that vasoinhibins are actually a family of peptides and
not a singular protein.71,72
The most interesting aspect of vasoinhibins is that their bioactivity seems to be in
opposition to that of whole PRL. While whole PRL has been shown to promote angiogenesis by
driving endothelial cell survival, proliferation, and migration,73 vasoinhibins most well
documented physiological effects are on endothelial cells include inhibiting vasodilation74,
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being potently anti-angiogenic.75,76 and promoting apoptosis of endothelial cells72 While the
mechanistic actions of vasoinhibins are not yet as well understood, recent work shows that
they are able to exert much of these effects through binding and inactivation of PAI-1 resulting
in anti-angiongenic and profibrinolytic effects.77
Vasoinhibins in general are extremely important to consider when studying PRL. Other
isoforms of PRL such as macroprolactin have been shown to cause false diagnoses of
hyperprolactinemia as it is recognized as PRL in many assays clinically used, but lacks much of
the biologic activity.78 Vasoinhibins could pose a similar risk as there is not clear evidence as to
the specificity of different detection methods and whether or not they are able to discern
between the two as the two protein types may share common epitopes. And given that
vasoinhibins have vastly different bioactivity, such oversights could have much larger
physiological consequences clinically.

Prolactin Receptor (PRLR)
The primary receptor through which monomeric PRL exerts its effects is the PRLR. This
receptor belongs to the hematopoietic receptor family and functions through a variety of
secondary messenger cascades, most notably the Jak-STAT pathway. The receptor has an
extracellular domain (ED), a transmembrane domain (TM), and an intracellular domain (IC)79.
The receptor can be modified in a variety of ways including alternative splicing of the mRNA as
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well as post translational cleavage. These processes result in 4 primary forms of the PRLR: the
long form, intermediate, and two short forms.80
The primary form of the receptor of physiological significance is the long form. However,
cells frequently express multiple forms of PRLR and can even heterodimerize two different
forms upon ligand binding resulting in an inactive complex81. It is thought that these inactive
complexes could also have physiological significance and provide a mechanism for dampening
PRL signaling, possibly helping to regulate which tissues respond to the signal and which tissues
don’t.81
Aside from such isoform complexity, the PRLR can also bind ligands other than PRL. GH
and PL can both bind the PRLR thanks to strong sequence similarities. While they bind to the
receptor with lesser affinity, it is believed to deliver the same signal.82

Role of Prolactin
In Immune Cells
The PRLR is expressed on all leukocytes.83 One of the most prevalent effects of PRL
treatment on the immune system is immunoproliferation. This proliferative action has been
most clearly demonstrated in the Nb2 T lymphoma cell line where a variety of cell growth
related genes are upregulated upon PRL treatment.84 Also administration of anti-PRL antibodies
is enough to inhibit lymphocyte proliferation in response to T and B cell mitogens in both
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mouse and human in vitro.85 It is important to mention however that many PRLR-/- models
have shown limited variation in immune profiles when compared to wild type86 and more
recent work has targeted PRL more so as a co-mitogen for proliferative factors such as IL-2
rather than exerting proliferative properties on its own.87,88
PRL also shows immune activating properties that follow a similar profile to their proproliferative properties where PRL is believed to act in concert with other signals rather than in
isolation, the effect often being stimulus dependent. The complexity of PRL signaling in the
immune system is evident in studies using whole blood where PRL treatment alone increased
levels of IL-10 and IL-12, PRL/LPS/PHA treatment increased IFNy and IL-12, but PRL/LPS
treatment increased levels of only Il-10.89 Such complexity can often make it difficult to predict
the systemic effects of PRL based on observed responses in isolated cells.
Finally, PRL has also shown anti-apoptotic effects in immune cells, the physiological
consequences of which are most evident in autoimmune diseases. Serum PRL levels have been
shown to be unusually high in a number of autoimmune diseases including systemic lupus
erythematosus, rheumatoid arthritis, and multiple sclerosis (MS).90 Studies in MS in particular
have shown that throughout pregnancy and post-partum, relapse rates closely correlate with
serum PRL levels.91 A more direct link between PRL and autoimmune diseases has been made
by showing that PRL interferes with tolerance induction in B cells, driving more autoreactive B
cells away from apoptosis, allowing them to survive into clonal expansion.90,92
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In adipose tissue
It was well established early on that significant changes in adipose tissue take place as
PRL levels fluctuate throughout pregnancy93. Even in isolation PRL appears tied to weight gain
as patients with hyperprolactinemia have increased body mass index (BMI), and the condition
can be corrected by administering the dopamine agonist bromocriptine that lowers PRL levels
back to normal.94
PRL has also been shown to act directly on adipocytes. This work began with the
discovery that adipocytes themselves express PRL receptors and can respond directly to the
hormone.95 In fact, PRLR expression increases up to 90 fold as preadipocytes differentiate into
mature adipocytes.95,96 Many subsequent studies highlight PRL as an adipogenesis promoting
hormone that acts by enhancing transcriptional regulators of adipogenesis such as PPARy 97 and
results in adipocytes with increased lipoprotein lipase expression and triacylglycerol content.98
Many of these findings are in accordance with in vivo studies where mice on high fat
diets (HFD) and PRL infusion show increased fat mass as a result of hyperplasia (increased
number of adipocytes), which is a metabolically healthier form of weight gain than hypertrophy
(increased size of individual adipocytes). PRL infused animals also showed a healthier metabolic
profile with increased adiponectin levels in greater insulin sensitivity despite the HFD.41
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CHAPTER TWO: ADRENERGIC HORMONES INDUCE EXTRAPITUITARY
PROLACTIN GENE EXPRESSION IN LEUKOCYTES – POTENTIAL IMPLICATIONS IN
OBESITY
Barrett, R., Narasimhulu, C. A. & Parthasarathy, S. Adrenergic hormones induce extrapituitary
prolactin gene expression in leukocytes-potential implications in obesity. Sci Rep 8, 1936,
doi:10.1038/s41598-018-20378-1 (2018).

Introduction to adrenergic hormones
Catecholamines are widely utilized signaling molecules throughout the body.
Biosynthesis of the catecholamines begins with the amino acid tyrosine which is converted to L3,4-dihydroxyphenylalanine (L-DOPA) via the rate limiting enzyme in catecholamine synthesis,
tyrosine hydrozylase. L-DOPA can then be converted to dopamine (DA), DA to norepinephrine
(NE), and finally NE to epinephrine (E), each step facilitated by its corresponding enzyme.99
Each catecholamine fulfills multiple signaling roles throughout the human body.
Dopamine is primarily considered for its role as a neurotransmitter and plays an important role
in a number of neurological diseases such as Parkinson’s disease where the death of
dopaminergic neurons leads to low DA signaling. 100 DA also plays a role in hormone regulation,
as mentioned earlier DA signaling in the anterior pituitary sharply inhibits PRL gene expression
and release from pituitary lactotrophs.101
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Diseases like Parkinson’s and hyperprolactinemia can both be treated by increasing DA
signaling to the tissues of interest such as the brain. However, DA is not particularly stable in
the human blood stream with a half-life on the order of a few minutes, so intravenous
injections have little benefit.102 Further DA is unable to cross the blood brain barrier (BBB) so
even if successfully delivered to the bloodstream it would be unable to reach its target sites. 103
As a result, L-DOPA has become a treatment of choice as it has both a longer half-life and is
capable of crossing the BBB. Being an important precursor for DA, increasing L-DOPA
concentrations result in increased DA levels in dopaminergic neurons.103
NE and E are collectively referred to as adrenergic hormones (AH). AH also play
important roles in neurological signaling, most notably in the classic “fight or flight” response
where they are quickly released from the peripheral nervous system and adrenal glands. In
congruence with such a role, many of their well-defined actions deal with energy redistribution.
One of their most potent signals is in the activation of hormone sensitive lipase (HSL) in
adipocytes. 104 Activation of HSL in adipocytes leads to an immediate cleavage of FFA from
triglycerides which can then be mobilized out of the cell and into the blood stream as an energy
source for other tissues.104 Proper signaling of AH is important in controlling overall lipid
metabolism whether small amounts of fat are mobilized for day-to-day energetic needs, or
whether large amounts of energy are mobilized at once as is needed in a “fight or flight”
response.104,105
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Materials and methods
Reagents
TRIzol™, primers, RPMI-1640, FBS, penicillin-streptomycin, and 1× PBS, were purchased
from Life Technologies (Carlsbad, CA). Superscript III cDNA kit and Sybr green were ordered
from Invitrogen (Carlsbad, CA). Phorbol 12-myristate 13-acetate (PMA), Sodium dodecyl sulfate
(SDS), urea, lipopolysaccharide from E. coli, L-DOPA, norepinephrine with bitartrate salt, and
epinephrine with bitartrate salt were purchased from Sigma-Aldrich (St. Louis, MO). IL-4 was
purchased from Promega (Madison, WI). Ficoll-Paque PREMIUM density gradient media
1.073g/mL was purchased from GE Healthcare Life Sciences (Pittsburgh, PA). Human prolactin
enzyme-linked immunosorbent assay (ELISA) kit was purchased from Boster Biological
Technology Co., LTD (Pleasanton, CA)

Cell Culture
Monocytes and macrophages were modeled using the THP-1 human monocyte cell line.
Cells were maintained in RPMI-1640 along with 10% FBS, 1% penicillin-streptomycin. THP-1
monocytes were differentiated to “naive” macrophages by supplementing media with 50 ng/mL
PMA for 72 hours. PMA was then rinsed away and “naive” macrophages were polarized to
either inflammatory “M1” macrophages with 100 ng/mL LPS for 24 hours, anti-inflammatory
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“M2” macrophages with 20 ng/mL IL-4 for 24 hours, or maintained in the basal medium for an
additional 24 hours to reduce the influence of PMA.

Figure 1: In vitro differentiation and polarization of THP-1 cell line

Isolation of Peripheral Blood Mononuclear Cells (PBMCs)
PBMC’s were isolated using Ficoll-Paque of a 1.073g/mL density, specifically formulated
for monocyte recovery from buffy coat and whole blood. Human buffy coat samples were
provided by One Blood (Orlando, FL). (Figure 2)
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Figure 2: Human buffy coat as received from One Blood Orlando

First, 50mL of buffy coat was diluted using 50mL RPMI. 20mL Ficoll-Paque PREMIUM
was then pipetted into a 50mL Falcon tube and 20mL of diluted human buffy coat was carefully
layered on top, with care to not allow mixing between the two layers. The tube was then
centrifuged at 400g for 40 minutes resulting in the formation of 4 layers: plasma, PBMCs, FicollPaque, and red blood cells along with other immune cells denser than 1.073g/mL. (Figure 3)
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Figure 3: Human buffy coat and Ficoll-Paque separation

After separation, the top layer of plasma was drawn off and PBMC’s were carefully
pipetted into another 50mL Falcon tube. The cells were then washed 4-6 times using RPMI to
remove platelet contamination and plated in RPMI supplemented with FBS. Cells were
incubated for 2 hours and any nonadherent cells were rinsed away. The remaining PBMC’s
were used for experimentation.
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Quantitative real-time PCR
Cells were dissolved in TRIzol™ reagent and RNA was isolated according to the
manufacturer’s instructions; cDNA synthesis was performed using 1 µg of total RNA.
Quantitative real-time PCR was performed on the CFX96 Touch™ Real-Time PCR Detection
System (Bio-Rad Laboratories, Hercules, CA) using SYBR Green as the detection dye. mRNA
expression levels of target genes were normalized against GAPDH.

ELISA
Medium was collected from experimental conditions and analyzed via ELISA. Sensitivity
of ELISA used was <1.0pg/mL with a suggested work range of 156pg/ml-10,000pg/ml PRL.
Protocols were according to manufacturer’s instructions. Readings were taken using a 96-well
plate reader (Benchmark Plus Microplate Spectrophotometer System, Bio-Rad, Hercules, CA).

Statistical Analysis
Values are presented as a mean ± standard deviation (SD), and statistical analyses were
performed using student’s t-test, with P < 0.05 as the cutoff level of significance.
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Results
Not all catecholamines stimulate PRL in THP-1s
Drawing from the knowledge that dopamine is the primary negative regulator of PRL
expression in the pituitary and that L-DOPA is the most commonly used drug to raise dopamine
levels in humans, we first tested high levels of L-DOPA in cell culture to see if it could also
influence ePRL expression in monocytes. Monocytes have been shown to express L-DOPA
decarboxylase, the enzyme necessary to convert L-DOPA to DA.106 However, no significant
change in PRL expression was observed in THP-1 monocytes except for a slight, insignificant
decrease in gene expression at 200uM, a concentration well beyond physiological levels. (Figure
4).

Figure 4: PRL expression in monocytes treated with L-DOPA
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Adrenergic hormones stimulate PRL expression
After observing no response with L-DOPA or dopamine, we moved on to the adrenergic
hormones NE and E. At the same supraphysiological concentrations originally tested with LDOPA a huge increase in PRL expression was observed; however, this response appeared
saturated and was not concentration dependent at these levels (Figure 5).

Figure 5: PRL gene expression in monocytes treated with E

We then tested concentrations reflecting physiological levels and observed a dose dependent
increase in PRL expression for both NE and E that was significant even at very low
concentrations (Figure 6).
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Figure 6: PRL gene expression in monocytes treated with physiological concentrations of NE
and E

Next we wanted to see if these changes in PRL gene expression corresponded to actual
increases in PRL produced by these cells. As mentioned earlier, monocytes are not capable of
storing PRL intracellularly as pituitary lactotrophs are, so all PRL produced by the cells is
thought to be directly excreted into the surrounding medium. With this in mind, we exposed
monocytes to varying concentrations of NE and E for 24 hours and measured the
concentrations of PRL protein in the medium via ELISA (Figure 7). PRL protein production
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closely followed genetic expression in monocytes treated with NE and E. Western blot analysis
was also performed on protein samples but was not used for analysis because of reoccurring
issues with antibody and low resolution.

Figure 7: Total PRL secreted into medium of monocytes treated for 24 hours

Effect of NE and E on freshly isolated PBMCs.
To determine whether this response is one specific to THP-1 cells alone or if could be
repeated using freshly isolated monocytes, we purchased buffy coat from One Blood Orlando
and isolated PBMC’s via the protocol detailed above. The results were somewhat muted in the
fresh PBMC population in response to NE and E and not much induction of ePRL was observed.
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However, the raw qRT-PCR data did show rather large error bars indicating variance between
the duplicate samples analyzed, suggesting that the working PBMC population may have been
somewhat distressed and as a result normal signaling may have been disturbed. As a result, we
cannot draw any confident conclusions from this data and further optimization of the protocols
will be necessary before this question can be answered. These results also leave open the
possibility that ePRL stimulation by adrenergic hormones could be a response specific to THP-1
monocytes as cell line biology can often drift from biology observed in the primary cells they
model.

Figure 8: PRL gene expression in PBMCs treated with A) NE and B) E for 24 hours
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Adrenergic stimulation occurs quickly with increases in gene expression evident within 2
hours and peaking at around 4-8 hours
In order to better understand the time course of adrenergic stimulation, THP-1
monocytes were exposed to 100nM NE and collected at different timepoints. Even at the
earliest timepoint of 2 hours an increase in PRL gene expression is evident. After about 4 hours
the cells seem to be responding fully with little change in expression there after. Sometime
after 8 hours the increase in PRL gene expression begins to return to baseline though the
response is still clearly observable at 24 hours (Figure 9).

Figure 9: PRL gene expression at different timepoints in monocytes treated with 100nM NE
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Differentiation and polarization of monocytes and macrophages influences basal PRL
expression
THP-1 monocytes were differentiated via the protocol above. Naïve macrophages
showed about a 6 fold increase in basal PRL expression over monocytes (Figure 10).

Figure 10: Basal PRL expression in monocytes and MDM

After an increase in gene expression was observed, we measured total PRL protein in
the medium of the samples after 24 hours via ELISA. PRL protein production through monocyte
differentiation closely mirrors the increase in gene expression with about a 10 fold increase in
PRL protein excreted into the medium. (Figure 11).
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Figure 11: Total PRL protein in medium of untreated monocytes and MDMs after 24 hours

After differentiation, MDMs were polarized via the protocol above. We measured basal
PRL gene expression between naïve (M0), inflammatory (M1), and anti-inflammatory (M2).
Successful polarization was verified using traditional genetic markers. The M1 population
showed a significant increase in TNFa and IL-6 expression confirming M1 polarization. The M2
population showed a significant increase in MRC-1 expression confirming M2 polarization. M2
polarized macrophages showed no significant difference in PRL gene expression compared to
M0. M1 macrophages however, showed an almost 5 fold increase in expression (Figure 12).
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Figure 12: Genetic expression of polarization markers and PRL in M0, M1, and M2 MDMs

To our surprise however, PRL protein production did not mirror PRL gene expression
across macrophage types. While M0 and M2 macrophages did show similar levels of protein
production as would be expected from genetic expression levels, M1 macrophages actually
showed a significantly reduced concentration of PRL in medium as compared to M0 and M2
macrophages. This was in direct opposition to the increase in PRL gene expression measured.
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Figure 13: Total PRL secreted into medium of macrophage types after 24 hours

Polarized Macrophages can be further stimulated with adrenergic hormones despite
increased basal expression of PRL
After observing that differentiation and polarization could increase basal PRL expression
in macrophages we set out to see if PRL expression could be further stimulated with adrenergic
hormones. M0, M1, and M2 macrophages were treated with 100nM NE and E for 24 hours. All
macrophage types could be further stimulated by both NE and E resulting in even higher ePRL
expression than the already elevated basal levels. (Figure 14)
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Figure 14: A) PRL gene expression in M0 MDMs in response to NE and E. B) PRL gene
expression in M1 MDMs in response to NE and E. C) PRL gene expression in M2 MDMs in
response to NE and E.

Upon measuring the total PRL protein released by MDMs stimulated with adrenergic
hormones, we noticed that the significant increase in expression observed from NE and E
treatment only amounted to a small, increase in total protein. Although an increase in protein
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was observed for almost all treatments, none of the results were significant although this could
likely be due to the smaller sample number. (Figure 15)

Figure 15: Total PRL measured in medium after 24 hour stimulation with 100nM NE or E in
A) M0 MDMs B) M1 MDMs and C) M2 MDMs

Much of the variance noted in the total PRL protein from the Figure 15 results actually
took place at a basal level in the controls. We observed rather large differences in the basal PRL
output from trial to trial that could have been due to a number of factors including different
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numbers of MDM’s originally seeded on the plate and natural variations in FBS used to culture
the MDMs. Because of this, fold increase in PRL protein output showed more consistent data
as, regardless of the basal level observed in the controls, the increase from adrenergic hormone
treatment was rather consistent (Figure 16). Such analysis brought many of the data points
much closer to significance although the low sample number still made the benchmark of pvalue 0.05 difficult to obtain.

Figure 16: Fold increase in PRL measured in medium after 24 hour stimulation with 100nM NE
or E in A) M0 MDMs B) M1 MDMs and C) M2 MDMs
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Other factors that affect the PRL response
During our experimentation, treatment with adrenergic hormones consistently resulted
in an increase in PRL expression; however, the degree to which expression increased varied
considerably. Some trials increased as little as 1.1 fold while other responded with over 40 fold
increases in expression. Seeing as this is a newly established response, we wanted to
investigate whether any of our culture or handling conditions could have an effect on the PRL
response. Altering many culture conditions such as temperature, FBS lots, confluence at time of
experiment, and passage number presented no clear and repeatable effects on the PRL gene or
the response to adrenergic hormones. However, the presence of serum greatly affected the
degree to which monocytes responded to adrenergic hormones. Although cells would respond
under serum free conditions, running the same experiment without starving cells resulted in an
almost 4 fold greater induction of the PRL gene at 6 hours. (Figure 17)
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Figure 17: PRL gene expression in THP-1 monocytes at 6 hours with and without serum

Discussion
Overall, our results clearly show that ePRL expression increases as monocytes
differentiate into MDMs and that adrenergic hormones are able to increase ePRL expression to
some degree in both. These two findings alone could have important implications in how
macrophages can influence overall adipose tissue fitness and function.
As previously mentioned, while the specific actions of PRL on adipocytes have been
somewhat muddled and at times conflicting depending on the methods used, there is a clear
consensus that PRL does indeed influence adipocyte biology. Some of this confusion could be
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brought about by the fact that much of the work up till now has only considered PRL as an
endocrine hormone derived entirely from the pituitary. While this assumption may hold true in
mice, it neglects an important source of the hormone in humans.
This fact is particularly important when considering our data showing a large increase in
PRL expression as monocytes differentiate into macrophages. An influx of MDMs into the
adipose tissue is a hallmark of obesity. Even when not accounting for other stimulatory factors,
this increase in basal PRL production alone could cause drastic changes in adipose physiology
via paracrine signaling. Further, it is likely this signaling could be overlooked entirely if only
monitoring serum levels of the hormone. Human PRL has been shown to have heparin binding
properties107 and seeing as adipose tissue is comprised of large amounts of heparin sulfate
proteoglycan rich connective tissue, which has been shown to trap growth factors with such
properties108, it is most likely that PRL produced at such sites would accumulate there with only
a smaller percentage leaking into circulation.109 Thus, macrophages ePRL could be exerting far
greater effects on adipose tissue than what is reflected in serum levels.
Secondly, our results show that ePRL expression is increased in the presence of
adrenergic hormones. Seeing as adrenergic hormones are primary signaling molecules for
lipolysis in adipose tissue and that PRL has been shown to exert anti-lipolytic effects on
adipocytes, these results suggest a possible opposing role between the two signals. ePRL
released in response to normal adrenergic signaling could result in a dampening of the signal.
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This could lead to less efficient lipid metabolism in the human system overall as lipids are able
to be stored in adipocytes but are not able to be effectively mobilized into the bloodstream
during times of high energetic demand.
Our results on how macrophage polarization effects ePRL expression are less clear.
While M0 and M2 macrophages appear to have generally similar ePRL regulation, M1
macrophages show significantly higher basal gene expression while at the same time showing
lower production of the actual protein. This could be for a variety of reasons. For one, mRNA
levels do not always accurately reflect protein production and although M1 macrophages show
higher levels of transcription of the gene, translation of the mRNA to a protein could be stalled
by another mechanism. Secondly, consumption of PRL could be increased in M1 macrophages
to the point where it overtakes an increased production rate. And thirdly, it is possible that M1
macrophages have mechanisms to degrade PRL. As mentioned earlier, cleavage of PRL results in
a bioactive 16kDa fragment referred to as vasoinhibin. It is possible that M1 macrophages
express one of the proteases necessary to cleave PRL at high levels into vasoinhibin or other
fragments. Because ELISAs rely on antibody recognition of a specific epitope in the protein,
such alterations could render PRL unrecognizable by the assay, thus reporting much reduced
levels. This second possibility in particular could have important biological implications in itself
and is worthy of further exploration.
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It is also interesting to note that the presence of serum played a significant role in the
magnitude of the ePRL response to adrenergic hormones. It is unknown whether an important
cofactor in the signaling process is present in the medium. It is also possible that the nutritional
status of the monocytes and MDM’s may play a large role in the magnitude of the response and
that the fasting state could downregulate this signaling.
For now, these conclusions are speculative and further work will need to be done to
determine if these signaling responses play out in vivo and to what degree such responses
influence human physiology. If so, this could open up an avenue of new diagnostics and
potential treatment targets. Understanding how hormones are regulated within the very
tissues they exert their effects is of vital importance when treating patients suffering from such
hormone imbalances and understanding such complex signaling is a necessary first step in
developing drugs and therapeutics that can help alleviate such imbalances.
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CHAPTER THREE: REGULATION OF PRL IN MONOCYTES AND MACROPHAGES
BY ADIPOSE STEM CELLS
Materials and Methods
Reagents
Transwell polyester membrane cell culture inserts of 12mm diameter and 0.3 μm pore
size were purchased from Corning Inc. (Corning, NY). DMEM:F12 and Hank’s balanced salt
solution (HBSS) were purchase from Life Technologies (Carlsbad, CA). Amicon ® Ultracel 3kDa
2mL Centrifugal Filters were purchased from Millipore Sigma (Burlington, MA). All other
materials are same as mentioned in Materials and Methods from Chapter 2.

Cell Culture
Adipocytes were modeled using the Simpson-Golabi-Behmel syndrome (SGBS) preadipocyte cell line kindly provided by the Dr. Martin Wabitsch lab at the University Clinic for
Paediatrics Ulm. Cells were maintained in DMEM:F12 and differentiated via the protocol
provided by Dr. Wabitsch based on his previous publications.110,111 The mediums referred to are
detailed in Table 1.
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Table 1: Assorted SGBS mediums and their components
Ingredient

Final Amount/Concentration
0F medium (serum-free basal medium)

DMEM:F12
Pantethenate
Biotin
P/S

To 500mL
17uM
33uM
5mL

Serum-containing medium (0F + 10% FBS)
0F medium
FCS

To 500mL
50mL
Freezing Medium

0F medium
FBS
Glycerol

8mL
1mL
1mL
3FC Medium

0F Medium
Transferrin
Insulin
Cortisol
T3

To 500mL
0.01 mg/mL
20nM
100nM
0.2nM
Quick-Diff Medium

0F Medium
Transferrin
Insulin

To 500mL
0.01 mg/mL
20nM

Cortisol
T3
Dexamethasone
IBMX
Rosiglitazone

100nM
0.2nM
25nM
250uM
2uM
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SGBS preadipocytes (SGBS-PA) were maintained in serum-containing medium for
routine growth and maintenance. For differentiation protocol, SGBS-PA were handled as
follows:
Cells were allowed to grow to near confluence (~80-90%) in 12 well plates. Cells were then
washed with PBS and Quick-Diff medium was added. Cells incubated in Quick-Diff medium for 4
days. At day 4, Quick-Diff medium is removed and replaced with 3FC medium (cells are not
washed between mediums). Cells are then cultured in 3FC medium for at least 8, and no more
than 12 days with 3FC medium changed every 4 days. In most cases, differentiation took place
over exactly 12 days.

Figure 18: Flow chart of adipocyte differentiation protocol

Differentiation of SGBS-PA to mature adipocytes (SGBS-MA) is a clearly visible process as
lipid droplet formation is a key step in adipogenesis and the lipid droplets are clearly visible by
light microscopy, even without the use of stains.
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Figure 19: A) SGBS-PA B) SGBS-MA
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While lipid droplets are easily identifiable under normal unstained conditions, we also
performed Oil Red O staining to confirm that they were in fact lipid droplets consisting of
neutral lipids (Figure 20.) In this particular experiment, there was a lower level of differentiation
so undifferentiated SGBS-PA are clearly visible at the top, unstained by the Oil Red O.

Figure 20: Oil Red O stain of differentiated SGBS adipocytes

Lastly, although differentiation appeared clearly visible based on changes in morphology
alone, we measured expression of key genes associated with adipocyte differentiation.
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Adiponectin, glucose transporter type 4 (GLUT4), and LPL all showed substantial increases in
expression, in line with complete adipocyte differentiation. (Figure 21)

Figure 21: Primary markers of adipocyte differentiation

We also measured other genes typically associated with adipocyte differentiation which
all showed increases in expression through differentiation. Two housekeeping genes showed no
significant change in expression. GAPDH was used to normalize genetic expression. (Figure 22)
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Figure 22: Genes relevant to adipocyte differentiation

Coculture methods
Cocultures were performed in two ways. The primary coculture method used 12-well
plate transwell chamber inserts. SGBS-PA and SGBS-MA were cultured in standard 12-well
plates for experimentation. THP-1 cells were then loaded into the upper chamber, inserted into
the appropriate well, and allowed to interact for 24 hours. In the case of coculture with
macrophages, THP-1 monocytes were differentiated onto the transwell chamber inserts using
the aforementioned protocol and then placed into coculture (Figure 23).
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Figure 23: Depiction of transwell coculture system

In the case of SGBS-PA/monocyte coculture, a direct coculture was also possible. SGBSPA were cultured to confluency in a 12-well plate and then monocytes were added for 24
hours. Monocytes are a suspension cell and were easily washed off of the firmly adhered SGBSPA and taken for analysis. SGBS cells from these experiments were not analyzed do to difficulty
of removing all THP-1 contaminants. This method of coculture was only used to see if direct
contact was necessary for signaling, once it was confirmed that direct contact was not
necessary, direct coculture was no longer used as it was not directly comparable across all cell
to cell interactions.
Conditioned medium was prepared by rinsing SGBS cells with serum free DMEM:F12
two times and then culturing cells with serum free DMEM:F12 for 24 hours. Starvation of SGBS
cells was performed by continuing this serum free culturing for the indicated length of time,
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changing medium every 4 days. Starved SGBS conditioned medium was obtained by applying
fresh medium for 24 hours at the indicated number of days.

Results
SGBS pre-adipocytes stimulate PRL expression in THP-1 monocytes under normal culture
conditions
Once the SGBS cell line was established in our laboratory, the first set of experiments
performed were direct coculture using THP-1 monocytes and SGBS-PA. After a 24-hour
coculture, monocytes were removed and ePRL expression was measured via qRT-PCR.
Monocytes from coculture consistently showed about a 30-fold increase in PRL expression over
controls. This increase in PRL expression did not appear greatly affected by the number of SGBS
cells in coculture as SGBS confluency from 50%-100% was tested with little difference in the
increase in PRL expression at 24 hours. (Figure 24)
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Figure 24: PRL gene expression in monocytes cocultured with SGBS-PA

SGBS cells also express the PRL gene although at far lower basal levels than THP-1
monocytes. Originally, it appeared as if coculture with monocytes also increased PRL expression
in SGBS pre-adipocytes; however, upon further experimentation this appeared to be due to
monocyte contamination in the SGBS sample. While monocytes can be cleanly removed from
the SGBS cells adhered to the bottom with gentle pipetting, many stay behind contaminating
the SGBS sample. For this reason, only monocytes were analyzed in direct coculture
experiments.
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SGBS-PA stimulate PRL in THP-1 monocytes in transwell coculture and with SGBS
conditioned medium
To test whether PRL is being stimulated through a contact dependent mechanism we
proceeded to indirect cocultures via transwell inserts as described above. This allows cells to
signal back and forth through a porous membrane, but not to come into direct contact with
each other. After a 24 hour coculture we again observed an almost identical increase in PRL
expression in monocytes lending us to believe that the response is likely triggered by a factor or
factors released into the medium. (Figure 25)
Lastly, we wanted to investigate whether continuous crosstalk between
monocytes and SGBS-PA was necessary for the ePRL stimulating response or whether
unstimulated pre-adipocytes constitutively altered the media in a way that caused such a
response. This was done by allowing SGBS-PA to condition serum free medium for 24 hours and
then subsequently exposing THP-1 monocytes to this “conditioned medium” for 24 hours.
SGBS-PA conditioned medium (PA-CM) was able to significantly increase PRL expression in THP1 monocytes and almost identical increases in PRL expression were observed regardless of the
method used. These results show that whatever factor increases PRL expression in the
monocytes is constitutively expressed by preadipocytes and does not require interaction with
the monocytes on the preadipocytes side.
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Figure 25: PRL gene expression in monocytes exposed to SGBS-PA through different methods

We were also able to determine a timeline for PRL gene response. PA-CM treatment
showed the greatest increase in PRL gene expression early on at 6 hours (Figure 26). Such a
robust response within 6 hours leads us to believe that PRL is directly stimulated by PA-CM and
not an eventual target of some downstream cascade. Increases in PRL gene expression were
noted as early as 2 hours. (Data not shown)
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Figure 26: PRL gene expression in monocytes exposed to PA-CM at different time points

A decrease in TNFa expression is observed alongside PRL stimulation from CM
There have been many reports showing that ASC have capacity to suppress
inflammation. While undifferentiated SGBS cells are typically referred to as “pre-adipocytes”,
they also fall under the category of ASC and have been used as a model in studies investigating
ASC secretomes.112 With this in mind we decided to investigate whether TNFa expression, a
classical marker of inflammation, had also been effected by our PA-CM treatments. We found
that in all cases where PRL had been upregulated in both monocytes and macrophages TNFa
was downregulated. Further, the degree to which TNFa was downregulated seemed to
correlate with the degree to which PRL was upregulated. Experiments with higher induction of
PRL also saw greater downregulation of the TNFa gene.
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Figure 27: TNFa gene expression in monocytes treated with PA-CM

MDMs treated with PA-CM show increase in ePRL expression and decrease in TNFa
expression
Our previous work showed that macrophages have an increased basal level of PRL. In
order to investigate whether SGBS-PA were able to influence this already increased basal PRL
expression, the above experiments were performed using THP-1 MDM differentiated via the
protocol outlined in Chapter 2. Here we see that ePRL gene expression does increase in MDM’s
although only about a third of the fold expression increase seen in monocytes.
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Figure 28: A) PRL and B) TNFa gene expression in MDMs after 24 hours

PRL protein production mirrors gene expression in monocytes and MDMs treated with
PA-CM
To measure whether or not protein production follows the expression patterns
observed above, we took medium from three PA-CM treated monocyte experiments and three
PA-CM treated MDM experiments and compared them against their controls from the same
experiment. We also tested PA-CM itself for PRL and although there have been reports of
adipocytes producing ePRL de novo113, we were unable to measure any PRL in the medium,
allowing us to assume that all PRL detected from these experiments would be monocyte and
MDM derived.
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We see a clear increase in ePRL protein production from both monocytes and MDMs
exposed to PA-CM. Shown together, it is also easier to appreciate that while treated MDMs do
not show as drastic of a fold increase in PRL expression when compared to treated monocytes,
their overall increase in ePRL protein output is quite substantial, resulting in almost 10x more
protein being secreted in the same time period.

Figure 29: ELISA data for monocyte PA-CM treatment (left pair) and MDM PA-CM treatment
(right pair).
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SGBS preadipocytes lose their ability to stimulate PRL in monocyte/MDM when
differentiated to mature adipocytes.
In order to study our initial aims of understanding how monocyte/macrophage derived
PRL may influence adipocyte biology we differentiated the SGBS-PA into mature adipocytes
(SGBS-MA) and repeated the transwell coculture and conditioned medium experiments.
Differentiation percentages were consistently around 90% meaning that some undifferentiated
preadipocytes remained in the culture system although at minor levels.
To our surprise, SGBS-MA no longer retained the ability to increase PRL expression in
either monocytes or MDMs in either coculture or via conditioned medium. In fact, in some
trials PRL gene expression was actually decreased compared to that of controls. This failure to
increase PRL gene expression was reflected in the medium as no significant change in PRL
protein concentration was measured for monocytes or macrophages treated with CM from
mature adipocytes. (Figure 30)
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Figure 30: A) PRL gene expression in monocytes cocultured with MA. B) PRL gene expression
in MDMs cocultured with MA.

Serum starved preadipocytes lose their ability to increase PRL expression in
monocyte/macrophage
The differentiation process for the SGBS preadipocytes requires the cells be serum
starved during the 12 day period of differentiation. In order to provide a more appropriate
comparison between our SGBS-PA results and SGBS-MA studies, preadipocytes were also serum
starved for 12 days and used in parallel with SGBS-MA. DMEM:F12 is designed to promote
cellular survival even in the absence of serum and SGBS-PA showed no sign of stress or
apoptosis even when serum starved for periods longer than 1 month. However, serum starved
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preadipocytes did cease to proliferate and a slight decrease in size was evident that became
more noticeable with longer starvation time periods.
Surprisingly, preadipocytes starved for 12 days no longer retained any of their previous
ability to increase PRL expression in monocytes and macrophages in coculture or via CM.
(Figure 1)

Figure 31: A) PRL gene expression in monocytes cocultured with starved PA. B) PRL gene
expression in MDMs cocultured with starved PA.

Since our CM itself is produced with serum free medium and SGBS-PA are still releasing
the unknown factor within day one of serum starvation, we wanted to measure how different
durations of serum starving affect SGBS-PA ability to condition the medium. We measured the
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effect of the CM from 0 day (0d), 1d, 4d, 8d, and 12d starved SGBS-PA and immediately noticed
a significant drop in the cells ability to stimulate PRL in monocytes after just 1 day starvation.
(Figure 32) Despite this immediate decrease, the PA-CM did maintain the ability to stimulate
PRL expression in monocytes even after multiple days of serum starving, though in general, the
greater the time of serum starvation, the lesser the ability of the CM to stimulate PRL in the
monocytes.

Figure 32: PRL gene expression in monocytes treated with CM from PAs serum starved for the
indicated number of days
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Interestingly, we again noticed TNFa gene expression indirectly correlating with PRL
gene expression. Longer starvation of the SGBS-PA amounted to an attenuated ability to lower
TNFa expression.

Figure 33: TNFa gene expression in monocytes treated with CM from PAs serum starved for
the indicated number of days

Unknown factor stimulating PRL in monocytes and macrophages is under 3kDa
Our original intent was to use mass spectrometry to help identify the possible factor
transferring the PRL stimulation signal from preadipocytes to monocyte/macrophage. Our mass
spectrometry setup allowed analysis of molecules under 3kDa in mass. In order to explore the
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feasibility of using this method for analysis we ran PA-CM from proliferating preadipocytes
through 3kDa centrifuge filters. After centrifugation, a low molecular weight (LMW) fraction
was isolated as wash-through. The high molecular weight (HMW) fraction consisted of the
portioned retained by the filter, resuspended in serum free medium. This fraction was obtained
by running the medium in the opposite direction through the filters as to collect and resuspend
the larger molecular weight components, such as most proteins, filtered out. These two
fractions were then compared in their ability to stimulate PRL.
The LMW fraction maintained much of its ability to stimulate PRL in monocytes although
slightly reduced. The HMW fraction maintained very little if any of its ability to stimulate PRL
(Figure 34). The slight stimulation seen from the HMW fraction is likely due to LMW factors left
over after filtration, as complete filtration was not feasible using these filters. From 2mL of
starting CM, about 200uL was consistently left in the upper chamber after filtration and trials
with a more complete filtration showed lower induction from the HMW fraction. However, we
cannot rule out that whatever factor being released could be around 3kDa, a common size for
many peptides, thus resulting in incomplete filtration.
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Figure 34: Effect of different PA-CM fractions on monocyte PRL expression

Complete medium is required for transferring PRL stimulating signal
In order to gain a better understanding of what type of factors could be influencing
signaling from SGBS-PA to monocytes and MDMs, we repeated our experiments using HBSS.
Small molecule biosynthesis frequently relies on a steady supply of precursors from the
medium so by minimizing medium contents to only salts and buffers, we would expect to see a
reduction in the ability of SGBS-PA to condition the medium.
Using HBSS as the culture medium resulted in a drastic decrease in the ability of SGBSPA to condition the medium; however, some stimulation ability was retained and just over a 2
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fold increase in ePRL expression was observed in monocytes upon exposure to HBSS PA-CM
(HCM). This was in comparison to about a 25-fold increase in expression for monocytes and a
10-fold increase in MDMs treated with DMEM:F12 conditioned medium (DCM). Another
interesting effect of HBSS in these experiments is that it resulted in 2 and 3 fold decrease in
basal ePRL expression in monocytes and MDMs respectively. (Figure 35)

Figure 35: PRL gene expression in A) monocytes treated with PA-CM B) MDMs treated with
PA-CM

Next we wanted to narrow down possible pathways involved in SGBS-PA signaling by
returning selected amino acids to the medium and seeing if it rescued the SGBS-PA ability to
condition HBSS. Our first goal was to investigate whether ePRL regulation from SGBS-PA could
be through adrenergic hormones, a mechanism we showed previously, or by some other
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catecholamine pathway. For this, we made a media formulation with aromatic amino acids
(Aro) that contained tryptophan, phenylalanine, tyrosine, histidine, and also cysteine. Tyrosine
and phenylalanine are precursors to most all catecholamines and tryptophan is a precursor to
serotonin, another more distant member of the catecholamine group. If the SGBS-PA were
signaling via these molecules or their byproducts, we would expect to see an increase in the
ePRL stimulating ability of the CM by providing these precursors. We also tested amphipathic
amino acids (Amp) containing lysine, arginine, proline, and also cysteine. These amino acids are
important mediators of a variety of metabolic pathways.
Addition of our selected amino acids yielded negative results as neither aromatic or
amphipathic amino acids were able to rescue PA-CM conditioning ability. This line of testing
was continued using a variety of other amino acid concoctions (data not shown), none of which
were able to return more than a 4 fold response to PA’s ability to condition HBSS. (Figure 36)
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Figure 36: PRL gene expression in monocytes treated with PA-CM of different basal medium
formulations

To make sure that HBSS as culture medium did in fact cause the ablation of SGBS-PA
ability to stimulate ePRL in monocyte/MDM, we also ran ELISA to determine PRL protein
content in the medium of the trials. Protein levels reflected the genetic expression changes
with monocytes having no detectable protein in either control or treated and MDM’s having
markedly reduced levels compared to those in DMEM:F12. MDM protein data however, does
reflect the finding that some stimulative ability is maintained in HBSS after 24 hours, although
this is also reduced.
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Figure 37: PRL protein content in medium of monocytes and MDMs treated with HBSS PA-CM

CM treated monocyte gene array
For the monocyte vs. PA-CM treated monocyte gene array we used the same cells from
the original ELISA experiments that showed the increase in secreted PRL into the medium after
24 hour PA-CM treatment. The RNA was extracted in house and sent to Qiagen to perform the
service. Seeing as few studies have been done in respect to immune production of ePRL, we
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selected a wide reaching array covering genes from the following signaling pathways: TGFβ,
WNT, NFκB, JAK/STAT, p53, Notch, Hedgehog, PPAR, oxidative stress, and hypoxia.
Upon initial review we noticed a variety of genes significantly up regulated (Table 1)
and downregulated (Table 2) in CM treated monocytes. Some of the most heavily upregulated
(over 2 fold increase) genes include: PPARD, ICAM1, LRG1, SOCS3, BTG2, FAS, LFNG, and FTH1.
While genes from many of the pathways are both upregulated and downregulated, it appears
that overall genes from STAT-induced, p53, Notch, and Oxidative pathways seemed generally
upregulated.

Table 2: Genes significantly upregulated in monocytes treated with ASC CM
Gene

P-value

Pathway

HERPUD1

Fold
Change
1.54

0.00131

TGFβ

TNFSF10

1.48

0.00026

TGFβ

DAB2

1.82

8.9E-05

WNT

PPARD

2.41

4.3E-05

WNT

ICAM1

2.18

0.00406

NFκB

STAT1

1.31

0.00505

NFκB
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Gene

Fold
Change

P-value

Pathway

IRF1

1.14

0.02828

JAK1 & JAK2 / STAT1

CEBPD

1.44

0.0194

STAT3-Induced

MCL1

1.35

0.00327

STAT3-Induced

LRG1

2.55

1.1E-05

STAT3-Induced

SOCS3

4.40

0.00088

STAT3-Induced

BBC3

1.45

0.04398

p53

BTG2

2.85

0.00089

p53

CDKN1A

1.35

0.00122

p53

FAS

2.04

0.01478

p53

ID1

1.39

0.02793

Notch

JAG1

1.42

0.00441

Notch

LFNG

2.92

4.7E-05

Notch

ACSL4

1.37

0.00238

PPAR

FTH1

2.14

2.2E-05

Oxidative

SLC2A1

1.40

0.01056

Oxidative

SQSTM1

1.19

0.00173

Oxidative

VEGFA

1.5948

0.00834

Oxidative

ARNT

1.37

0.00263

Hypoxia
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The most heavily downregulated genes (0.50 cutoff) include: EMP1, FCER2, and BCL2. Of
particular note though, is the downregulation of TNFa by 0.56, a downregulation similar to
what we frequently observed in the lab. Downregulated genes include many inflammatory type
genes from the TGFβ and NFκB pathways as well as oxidative stress pathway.
As mentioned before, many genes from these pathways were both up and
downregulated. CM is constituted of many different factors and it is likely that some of these
factors have counteracting roles causing genes within the same pathway to react differentially.
Also, many genes respond in as little as 4 hours and having taken readings from a 24 hour
experiment, we cannot rule out that some of gene responses could be secondary or tertiary
responses as many genes stimulate negative feedback loops.
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Table 3: Genes significantly downregulated in monocytes treated with ASC CM
Gene

P-value

Pathway

ATF4

Fold
Change
0.7684

0.00223

TGFβ

EMP1

0.1539

0.00897

TGFβ

MYC

0.6721

0.00037

TGFβ/WNT

CCL5

0.7756

0.00688

NFκB

TNF

0.5586

0.00429

NFκB

FCER2

0.2892

0.03693

JAK1 & JAK3 / STAT6-Induced

PCNA

0.8665

0.01508

p53

HEYL

0.6071

0.03488

Notch

BCL2

0.4796

0.00638

Hedgehog

SLC27A4 0.6029

0.00932

PPAR

GCLM

0.7457

0.00401

Oxidative

NQO1

0.8726

0.00433

Oxidative

TXN

0.7738

0.02536

Oxidative
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Figure 38: First gene grouping from gene array heat map for individual monocyte samples
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Figure 39: Second gene grouping from gene array heat map for individual monocyte samples
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CM treated macrophage gene array
Compared to monocytes, MDM’s showed fewer genes responding to PA-CM. The genes
WISP1, and OLR1 show the highest fold induction of the upregulated genes. Also of note, LRG1
showed a large fold-increase although fell just short of the statistical significance cutoff of Pvalue 0.05. However, this was a gene also upregulated in monocytes so is worth considering.
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Table 4: Genes significantly upregulated in MDMs treated with PA-CM
Gene

Pathway

PPARD

Fold
P-value
Change
1.4439 0.00466

WISP1

5.5919

0.03771

WNT

BCL2A1

1.2142

0.03933

NFκB

CCND1

1.6396

0.0081

WNT

LRG1

3.3404

0.07589* STAT3-Induced

MCL1

1.2454

0.04986

STAT3-Induced

HES1

1.7818

0.02295

Notch

JAG1

1.4709

0.01025

Notch

NOTCH1 1.4743

0.00254

Notch

WNT6

1.2805

0.02048

Hedgehog

ACSL4

1.154

0.02365

PPAR

OLR1

4.801

0.00087

PPAR

FTH1

1.3287

0.0285

Oxidative

LDHA

1.1975

0.04153

Oxidative

SLC2A1

1.4675

0.00943

Oxidative

ARNT

1.3044

0.02746

Hypoxia

EPO

1.8067

0.04864

Hypoxia

WNT
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*large “fold change” but not significant
The most heavily downregulated gene (0.50 cutoff) was BIRC3 although CSF1, TNFa, and
FAS were close to the cutoff. Looking at the significantly downregulated genes as a whole
though, there is a clearer trend of inflammatory genes from the TGFβ and NFκB pathways being
downregulated.
Table 5: Genes significantly downregulated in MDMs treated with PA-CM

Gene

P-value

Pathway

ATF4

Fold
Change
0.7792

0.01722

TGFβ

BIRC3

0.3431

0.0011

NFκB

CSF1

0.6271

0.03346

NFκB

TNF

0.6314

0.01963

NFκB

FAS

0.5164

0.01574

p53

BCL2

0.7544

0.00274

Hedgehog

ACSL5

0.9096

0.03983

PPAR

GCLM

0.8293

0.01622

Oxidative
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Figure 40: First gene grouping from gene array heat map for individual MDM samples
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Figure 41: Second gene grouping from gene array heat map for individual MDM samples
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Discussion
The original goal in this line of experimentation was to investigate some of the
hypotheses developed during our adrenergic and macrophage differentiation work. We had
proposed that monocyte/macrophage ePRL expression would be altered in the presence of
mature adipocytes and in turn, ePRL could cause changes in how lipids were stored and
metabolized in adipocytes. While our data does not disprove such a relationship, it does lead us
in a different direction and suggests a more likely role for ePRL in adipose tissue homeostasis
may lie in tissue remodeling.
Our first set of surprising results came with our initial coculture experiments where PA
were able to stimulate ePRL in monocytes and MDMs but MA and serum starved PA had
essentially no effect on ePRL expression. It is difficult to pinpoint exactly what is causing such a
change in signaling as multiple variables are being altered at once during serum starvation and
differentiation. Clearly, with the removal of serum from the experimental conditions we are
removing a large number of signaling molecules that could be important precursors or
cofactors in the process of stimulating PRL in the immune cells. Also, removing these
components likely alters a variety of metabolic or other normal housekeeping pathways within
the cells of which a PRL stimulating factor could be a byproduct.
In line with serum removals effects on baseline pathways within a cell, we must also
take into account another similarity between MA and serum starved PA in that both groups of
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cells cease to proliferate. In the case of MA, this is a terminal differentiation after which no
more cell division can take place. For serum starved PA, it appears a component of the serum is
necessary for proliferation although serum free medium is sufficient for survival. Nonetheless,
we must consider that a PRL stimulating factor could be a byproduct of normal cell proliferation
or the pathways activated during the process. Experiments that could separate these two
variables, such as using an mTOR inhibitor to halt cell proliferation even in the presence of
serum, would prove useful in gaining a better understanding of which variables have the most
influence over this response and provide more insight into possible reasons for such a
response.
Another interesting phenomenon regarding medium requirements by the cells is the
observation that HBSS is unable to transfer PRL stimulation from the SGBS-PA to the immune
cells. While it’s clear that serum starvation alters the PA so that they are no longer able to
stimulate PRL, it is also interesting to note that even in PA that should be able to do so, full
medium is required.
We tried to take advantage of this finding by returning select amino acids to HBSS to see
if we could rescue the response. For instance, we theorized that the factor from SGBS-PA
involved in stimulating ePRL could be derived from catecholamine pathways in concert with our
initial findings on this project. To test this we supplemented aromatic amino acids to the
medium that are necessary precursors for all catecholamines. However, results from those
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experiments and similar amino acid supplementation were unable to return full competency to
the PA-CM. It is possible that another component of DMEM:F12 besides the amino acids we
tested is necessary for the response or that certain components together are necessary and
isolation of individual amino acids or amino acid groups is insufficient to return a full response.
Fractioning of the PA-CM also provided important insight into what is responsible for
PRL stimulation. The fact that the LMW fraction retains the majority of the ability to stimulate
ePRL allows us to rule out a large number of other possible components. For instance, 3kDa is a
cutoff for which all proteins should be removed which allows us to exclude a large number of
signaling pathways regulated by large proteins from consideration. However, this experiment
does less in the way of identifying exactly what is causing the response as the LMW fraction
could contain any number of small molecules, peptides, or nucleic acids.
Lastly, the most telling data collected throughout this project is analysis of the genes
that are regulated alongside ePRL as these give us the best sense as to what conditions cells
upregulate ePRL expression. In particular, we paid close attention to TNFa regulation, which
seemed to closely negatively correlate with ePRL expression although our line of
experimentation cannot delineate whether or not this is done by the same factor or a separate
factor that is released under similar conditions.
This anti-inflammatory correlation of ePRL was further supported upon analysis of our
gene arrays. We observed a variety of genes from different pathways that are known to be
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important markers and regulators for general anti-inflammatory polarization in macrophages.
For instance, we saw significant upregulation in PPARD, which acts as an important regulator of
lipid metabolism. Metabolic reprogramming to lipid metabolism and beta-oxidation is a
necessary step in M2 polarization and M2 macrophages cannot persist without PPARD
activation.114,115 Upregulation in other genes, such as ACLS4, that play vital roles in regulating
lipid metabolism116 also lead us to believe that PA-CM is capable of activating genes necessary
for an M2 metabolic reprogramming in the immune cells.
More directly, we see specific markers of inflammation regulated in ways that correlate
with an M2 phenotype when treated with PA-CM. In particular, the gene array shows
downregulation of TNFa consistent with our own gene expression studies throughout our work.
As mentioned before, TNFa expression closely negatively correlates with ePRL expression in our
studies. Other inflammatory markers such as CSF1 and ATF4 were also shown to be
downregulated. Also, after observing a variety of gene regulation hinting at M2 polarization, we
also ran follow-up analysis for IL-10 and MRC1 expression, both key markers of M2 polarization.
Interestingly, we saw a significant increase in IL-10 expression but did not see a significant
increase in MRC1 expression.
Also of note, we observed upregulated genes involved in both angiogenesis and growth
and development. WISP1 for example plays a role in mesenchymal stem cell proliferation and is
a pro-mitogenic and pro-survival factor.117,118 Other genes like LRG1119, OLR1120, and ARNT121 all
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play a role in growth and angiogenesis. OLR1 is of interest to the laboratory as this protein is
suggested to recognize and internalize oxidized low density lipoprotein (Ox-LDL). Ox-LDL levels
are increased in atherosclerosis, for which obesity is a known risk factor.
It is also interesting to note that many JAK/STAT pathways are upregulated in our PACM treated groups. In particular, we see a strong upregulation of SOCS3. These changes are of
note because multiple STAT proteins are downstream targets of PRL signaling and genes such as
SOCS3 have been shown to be directly regulated by PRL signaling.122 Such regulation is likely the
result of our time point chosen. We ran the gene array on our 24 hour treated samples from
our ELISA experiment because the protein analysis gave us a high level of confidence that the
experiment ran well and consistently. However, clearly being able to measure PRL in the
medium means that cells were subjected to this signal at the time points tested and were likely
already responding to their own PRL secretion. The effects of secondary and tertiary signaling
could be more clearly defined by performing gene array at earlier time points but this was cost
prohibitive for our laboratory. Nonetheless, it does lend credence to previously published work
that ePRL functions in an autocrine fashion for immune cells.66,123
Our line of experimentation yields new insights on ePRL regulation in monocytes and
macrophages. While our initial hypothesis was that ePRL played a primary role in modulating
lipid metabolism and would thus more strongly respond to lipid loaded mature adipocytes, our
observations throughout this course of study have yielded a surprising outcome that ePRL is far
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more responsive to factors released by PA. In particular, it is important to remember that PA
are in fact ASC and more broadly, mesenchymal stem cells. PRL as a growth and differentiation
promoting hormone meshes well with these concepts. And the fact that much of the genetic
regulation taking place alongside PRL induction also follows that general theme bolsters the
idea that PRL may play an important role in stem cell development, growth, and tissue
remodeling.
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CHAPTER FOUR: CONCLUSION
The role of the immune system, and more specifically ATM, in non-classical functions
such as tissue homeostasis is only beginning to be unraveled despite a flurry of recent research
on the topic. We are beginning to understand that pathogen elimination is only a single arrow
in the quiver available to these complex and plastic cells and that they in fact have a hand in
almost every major process in the human body. On top of this complexity, we are uncovering
more and more ways in which these cells differ between humans and many of the most
common animal models such as mice and rats. Recent work on ePRL production shows how
even in cases where the protein and signaling pathways vary little between species, millions of
years of evolution can result in drastic differences in how the protein is expressed and
distributed. It is of upmost importance to consider such differences when translating findings
from animal models into the clinic and a better understanding of such nuances can hopefully
increase the success of drugs and therapeutics as they progress into humans.
Originally we had set out to study how monocyte and macrophage derived PRL is
regulated in the presence of mature adipocytes and whether or not such PRL responded to, or
could interfere with general cellular metabolism in mature adipocytes. Our initial results
showing that adrenergic hormones significantly increased PRL expression fit in well with this
hypothesis and suggested that the two signals could work in opposition, helping to regulate
each other through their opposing actions. Adrenergic hormones are well characterized as
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activators of lipolysis and PRL has been shown to inhibit lipolysis and is correlated with weight
gain across a number of studies.
The increase in PRL secretion observed as monocytes differentiate into macrophages
also suggested a physiological significance as a drastic influx of macrophages into adipose tissue
is observed in obesity. Even in the absence of stimuli, this increase in macrophage populations
alone would increase adipose tissue exposure to the PRL proteins. And seeing as PRL tends to
“stick” to proteoglycans on the surface of adipocytes113, much of this PRL burden would likely
be isolated to paracrine signaling within the adipose tissue and not be well reflected in total
serum levels.
However, the data from our experiments points us in a different direction. Both our
monocytes and macrophages show a significant and robust ePRL response when cultured with
adipose stem cells, from which the mature adipocytes are seeded, and have generally no
response to the mature adipose cells themselves.
While our line of experimentation cannot rule out that monocyte/macrophage-derived
PRL influences adipocyte metabolism, our results suggest that PRL may be more relevant in a
different context: when taken as a whole, it is clear that ePRL is being upregulated only in the
setting of a high growth environment. Whether monocytes/macrophages are responding to the
proliferating PA themselves, or factors in the serum used to stimulate growth in cell culture, we
cannot yet say. Also, looking at the gene regulation in monocytes/macrophages surrounding

87

the increase in ePRL, we see a general shift towards an M2 phenotype. While our previous work
does not show an increase in PRL expression upon M2 polarization, M2 polarization is far more
complex than a binary event and M2 subsets with very different functions such as M2a, M2b,
and M2c have been characterized along with tumor associated macrophages (TAM).124,125
Perhaps PA-CM influences into an M2 state more complex than simple IL-4 signaling and more
conducive to tissue remodeling.
Such a model makes sense when considering the massive changes in size that adipose
tissue is required to undergo within very short time frames. During times of high nutrition,
adipocytes must be able to undergo drastic increases in size as their lipid droplets swell to store
energy, and during times of low nutrition, there can be just as drastic a decrease in adipocyte
size in a matter of just weeks. All this must take place in a defined tissue space and must be
accompanied by restructuring of the extracellular matrix (ECM) and vasculature.126
Given that PRL is shown to play a role in a variety of processes relevant to such actions,
and that ePRL in monocytes and MDMs is upregulated along with other genes shown to play a
role in tissue growth and remodeling, our work points to ePRL as likely being a human specific
protein involved in this process. Further experiments will need to be performed in order to
show a more direct role for ePRL from immune cells in this role, but as mentioned earlier, the
goal of our research involving ePRLs regulation was to elucidate more about its possible
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function within the human body and I believe our results point in a clear direction for future
areas of experimentation.
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